Paradoxical Response to Antituberculous Therapy in Infliximab-Treated Patients with Disseminated Tuberculosis
Open Access
- 1 March 2005
- journal article
- case report
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 40  (5) , 756-759
- https://doi.org/10.1086/427941
Abstract
Six of 284 patients treated with infliximab developed active tuberculosis. Four (67%) of these patients had a paradoxical response to antituberculousKeywords
This publication has 12 references indexed in Scilit:
- Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical managementThe Lancet Infectious Diseases, 2003
- Clinical Spectrum of Paradoxical Deterioration During Antituberculosis Therapy in Non-HIV-Infected PatientsEuropean Journal of Clinical Microbiology & Infectious Diseases, 2002
- Infections in the immunocompromised rheumatologic patientCritical Care Clinics, 2002
- Tumor necrosis factor-α antagonists for the treatment of rheumatic diseasesCurrent Opinion in Rheumatology, 2002
- InfliximabBioDrugs, 2002
- AnastrozoleDrugs, 2002
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001
- InfliximabDrugs, 2000
- Paradoxical Reactions in HIV and Pulmonary TBChest, 1998
- Paradoxical Worsening of Tuberculosis Following Antiretroviral Therapy in Patients with AIDSAmerican Journal of Respiratory and Critical Care Medicine, 1998